Drug Approval | July 23, 2024
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Subscribe To Our Newsletter & Stay Updated
